Gufic BioSciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• Gufic BioSciences Ltd reported a 6.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.1%.
• Its expenses for the quarter were up by 4.4% QoQ and 23.7% YoY.
• The net profit increased 28.7% QoQ and decreased 22.7% YoY.
• The earnings per share (EPS) of Gufic BioSciences Ltd stood at 1.68 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gufic BioSciences Ltd is a pharmaceutical company known for its production and distribution of a variety of pharmaceutical products. The company operates within the healthcare industry, with a focus on manufacturing and marketing a wide range of formulations in therapeutic segments such as antibiotics, antifungals, and other healthcare-related products. The company has been involved in both domestic and international markets, consistently working towards broadening its product portfolio and market reach. However, specific recent developments or strategic initiatives undertaken by the company are not available within the provided information.

Revenue

For the second quarter of the fiscal year 2026 (Q2FY26), Gufic BioSciences Ltd reported a total income of ₹239.17 crores. This represents a quarter-over-quarter (QoQ) increase of 6.5% from the first quarter of fiscal year 2026 (Q1FY26), which recorded a total income of ₹224.65 crores. Compared to the same quarter of the previous fiscal year (Q2FY25), where the total income was ₹204.29 crores, there is a year-over-year (YoY) increase of 17.1%. These figures reflect the company's revenue growth over both the previous quarter and the same quarter last year.

Profitability

In terms of profitability, Gufic BioSciences Ltd achieved a Profit Before Tax (PBT) of ₹22.60 crores in Q2FY26. This reflects a 30.9% increase from the PBT of ₹17.27 crores recorded in Q1FY26. However, when compared to Q2FY25, where the PBT was ₹29.25 crores, there is a YoY decrease of 22.7%. The company's Profit After Tax (PAT) for Q2FY26 was ₹16.82 crores, an improvement of 28.7% from the ₹13.07 crores reported in the preceding quarter. The PAT shows a YoY decline of 22.7% from the ₹21.77 crores recorded in Q2FY25. The Earnings Per Share (EPS) for the current quarter stood at ₹1.68, increasing by 29.2% QoQ from ₹1.30, but decreasing by 22.6% YoY from ₹2.17.

Operating Metrics

The total expenses for Gufic BioSciences Ltd in Q2FY26 amounted to ₹216.56 crores, marking a 4.4% rise from the ₹207.37 crores in Q1FY26. Compared to the same period last fiscal year, where expenses were ₹175.04 crores, there is a YoY increase of 23.7%. Tax expenses in Q2FY26 were ₹5.78 crores, up by 37.6% from ₹4.20 crores in the previous quarter. This represents a YoY decline of 22.8% from the ₹7.49 crores recorded in Q2FY25. These metrics provide insight into the company's cost structure and tax obligations across different periods.